November 20, 2024
TOPLINE: Combining transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) was associated with a greater reduction in symptoms of major depressive disorder (MDD) […]
November 20, 2024
The well-being of doctors is under significant strain, with acute and chronic stress, psychological trauma, ethical dilemmas, and negative experiences contributing to burnout and depression. This […]
November 18, 2024
TOPLINE: Physical activity of any intensity after a diagnosis of dementia is associated with a significantly lower risk for all-cause mortality, a new study showed. Researchers […]
November 18, 2024
LISBON, Portugal — Europe needs a Child Health Exposome Mission to better understand how to prevent, diagnose, and treat diseases over the life course, protecting the […]
November 13, 2024
Emergency department (ED) visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder (SSD), results of a large population-based study […]
November 13, 2024
Canada’s National Guideline for the Clinical Management of Opioid Use Disorder (OUD) has been updated to reflect the latest literature. The new document recommends buprenorphine and […]
November 12, 2024
New research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD). In a 52-week phase 2 trial, personalized rTMS applied over […]
November 6, 2024
The combination of intranasal insulin (INI) and the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin had positive effects on cognition and immune and inflammatory biomarkers in patients […]
November 5, 2024
Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia […]